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Lower extremity angioplasty for claudication:
A population-level analysis of 30-day outcomes
Todd R. Vogel, MD, MPH, Leonard T. Su, MD, Rebecca G. Symons, MPH,
and David R. Flum, MD, MPH, Seattle, Wash
Objective: With the increased availability of lower extremity percutaneous transluminal angioplasty (PTA), the conven-
tional, noninterventional management of claudication may be evolving. This study evaluated changes in the use and
short-term outcomes of PTA among patients with claudication and other manifestations of peripheral arterial disease
(PAD).
Methods: A retrospective cohort study was conducted using the linked Washington State hospital discharge database
(CHARS). Cases included all patients undergoing inpatient lower extremity PTA from 1997 to 2004. Patients with
claudication were compared with those having PTA for other lower extremity diagnoses. The main outcome measures
were readmission, reintervention (angiography, angioplasty/stent, surgical revascularization, or amputation), and death
<30 days.
Results: A total of 1718 patients (mean age 69.7 11.2, 52.4% male) underwent PTA for claudication (51.9%), rest pain
(12.1%), ulceration (23.2%), or not otherwise specified (12.9%). Yearly PTA use nearly doubled between 1997 and 2004,
from 182 to 360, with a more dramatic increase in PTA among patients with claudication. Patients undergoing PTA for
claudication were younger (67.9 10.3 vs 71.7 11.7 years, P< .01), more likely male (58.2% vs 46.2%, P< .01), and
had a lower comorbidity index (0.7 vs 1.1, P < .01) compared with all others. A total of 65.3% were Medicare eligible.
Among 555 patients aged<65 years, the indication for PTAwas claudicationmore often when they had private insurance
compared with uninsured or Medicaid beneficiaries (70.3% vs 49.1%, P < .01). Patients with claudication had shorter
hospitalizations (2.4  2.3 vs 5.2  5.8 days, P < .01), lower rates of in-hospital death (0.8% vs 3.3%, P < .01), 30-day
mortality (1.2% vs 4.7%, P< .01), and 30-day readmission (10% vs 23.1%, P< .05). Reintervention was required in 28.1%
of readmitted patients with claudication, but none underwent amputation <30 days.
Conclusion: The use of PTA for claudication dramatically increased during the 8-year study period. Claudication was
more often the diagnosis for PTA in patients who were younger, healthier, and privately insured. PTA for claudication
had a higher-than-expectedmorbidity, 30-day readmission, and rate of reintervention. Future studies should focus on the
factors motivating the use of PTA, its associated outcomes, and global impact on patients and the health care system.
(J Vasc Surg 2007;45:762-7.)Lower extremity peripheral arterial occlusive disease
(PAD) is associated with substantial decrements in quality
of life and functional status, premature mortality, and has a
significant burden on health care resources.1-3 Estimates
are that by 2030, there will be 76 million people aged65
years, and as the population ages, the prevalence of PAD
will increased.4
The care of patients with vascular disease is undergoing
a revolution driven by endovascular and stenting technol-
ogy, the introduction of new practitioners into the field
who come from nonsurgical disciplines, and an aging pop-
ulation demanding invasive treatments to improve quality
of life and functional status. These changes in the approach
to patients with vascular disease have not been well studied
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762nor has their impact on individuals or the health care system
been assessed in a rigorous fashion.
With these recent developments, a shift in approach to
some patients with PAD appears to be occurring. Although
nationwide rates of lower extremity surgical revasculariza-
tion have remained stable or declined,5 nonsurgical endo-
vascular interventions for PAD have increased by at least
40% since 1996. Many practitioners describe femoropopli-
teal angioplasty as a primary treatment for patients with
claudication and also report high levels of success and low
risk.6 Despite the conventional noninvasive approach to
lower extremity claudication,7,8 the use of this technology
has increased.
We hypothesized that a significant increase occurred in
the use of lower extremity percutaneous transluminal an-
gioplasty (PTA) for claudication in recent years. We also
hypothesized that PTA for claudication is associated with
higher complication rates and readmissions than reported
in small, single-institution series. The purpose of this study
was to address these hypotheses on a population level and
to compare these rates with published results.
METHODS
Study design. A retrospective cohort study was con-
ducted using a statewide hospital administrative discharge
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1997 and 2004 were evaluated to assess the use and short-
term outcomes of PTA among patients with PAD.
Data source. Data were obtained from the Washing-
ton State Comprehensive Hospital Abstract Reporting Sys-
tem (CHARS). This data set is derived from all public and
private hospitals in Washington State (Veterans Affairs and
US military hospitals excluded). It contains demographic
variables, admission and discharge administrative details,
payer status, International Classification of Diseases, Ninth
Revision (ICD-9) procedure and diagnosis codes, and hos-
pital identifiers. CHARS also allows for tracking of subse-
quent hospitalizations and linkage to vital statistics records.
This study was granted an exception by agreement of the
University of Washington Human Subject Review Com-
mittee and the Washington State Department of Health.
The data set includes only anonymous data and is consid-
ered within the public domain.
Subjects. CHARS records from 1997 to 2004 were
searched to identify all cases of angioplasty as indicated by
the ICD-9 procedure code 39.50. Cases included in the
cohort were patients aged18 years undergoing peripheral
angioplasty determined by an evaluation of ICD-9 diagnos-
tic codes for PAD, including claudication, rest pain, ulcer-
ation and gangrene, and PAD not otherwise specified.
Angioplasty patients with associated renal, mesenteric, and
cerebral disease diagnoses were excluded.
Variable definitions. Patients were categorized by
PAD according to ICD-9 diagnosis codes for atherosclero-
sis of the extremities with claudication (440.21), athero-
sclerosis of the extremities with rest pain (440.22), athero-
sclerosis of the extremities with ulceration or gangrene
(440.23, 440.24), and atherosclerosis of the extremities
unspecified (440.20).
A modified version of the Charlson Comorbidity In-
dex9 was calculated for each patient. The Charlson mea-
sure, which has been adapted for use with administrative
claims, is a weighted index of comorbidity status based on
ICD-9 codes from inpatients’ records. Scores range from 0
to 3, where 0 indicates the absence of comorbid conditions
and a score0 indicates the presence and severity of one or
more comorbid conditions.
Outcomes assessed include in-hospital death, readmis-
sion, reintervention, and 30-day mortality. Readmissions
were defined as inpatient admissions30 days of discharge
from the index hospitalization. Reinterventions included
angiography, surgical revascularization, repeat angioplasty,
stent placement, or amputation, or a combination, as indi-
cated by ICD-9 procedure codes associated with the read-
mission record. In-hospital death is directly coded as a
discharge status for the index admission. The 30-day mor-
tality was defined as all-cause death 30 days of discharge
as ascertained from Washington State Vital Records.
Analysis. Descriptive statistics were calculated for the
entire cohort. Patients undergoing PTA for claudication
were compared with those undergoing PTA for other PAD.
Frequency of angioplasty procedures per year was calcu-
lated. Patient and hospitalization characteristics evaluatedinclude age, sex, comorbidity, admission type, length of
stay, discharge status, and insurance type. Outcomes eval-
uated include readmission, reintervention, and death. Cat-
egoric variables were compared using the Pearson 2 statis-
tic, and continuous variables were evaluated using analysis
of variance. A nonparsimonious, logistic regression model
was used to analyze the relationship between diagnosis type
and adverse outcome while controlling for available covari-
ates. Statistical analysis was performed using Stata 9 statis-
tical analysis software (StataCorp, College Station, Tex).
RESULTS
Demographic information. During the study period
(1997 to 2004), 1718 patients (mean age, 69.7  11.2
years; 52.4% male) had a lower extremity angioplasty pro-
cedure. The yearly use of PTA increased from 182 in 1997
to 360 in 2004, with greater than a doubling of the
indication for PTA being claudication (Table I). The indi-
cations for PTA were 51.9% for claudication, 12.1% for rest
pain, 23.2% for ulceration/gangrene, and 12.9% not oth-
erwise specified. Most inpatient PTA (78.6%) was elective
(Table II).
Group comparison. Compared with others (Table
III), patients undergoing PTA for claudication were
younger (67.9  10.3 vs 71.7  11.7 years, P  .01) and
had fewer comorbid conditions as demonstrated by signif-
icantly greater numbers with low comorbidity scores (49.2
vs 36.9, P  .05). Patients with claudication were more
likely to receive a lower extremity stent (67.0% vs 55.1%,
P  .01), be discharged to home (94.2% vs 66.3%, P 
.01), and to have private insurance (32.1 % vs 20.0%, P 
.01), and they had a shorter length of stay (2.4  2.3 vs
5.2  5.8 days, P  .01). The mean length of stay for
claudication interventions the first year of the study was
2.53  2.28 days, which decreased to 1.88  1.98 days.
Thirty-four (2.0%) patients died while in the hospital,
and 30-daymortality after PTAwas 2.9% (n 50). The risk
of periprocedural death for patients with claudication was
significantly lower compared with all other patients (1.2%
vs 4.7%, P  .01). After adjusting for age, sex, and comor-
bidity index, the odds of 30-day death among patients with
claudication was more than half as much as the risk for others
(odds ratio, 0.4; 95% confidence interval, 0.2 to 0.8).
The 30-day readmission rate for all patients was higher
Table I. Annual number of procedures by diagnosis
Year All others Claudication Total
1997 91 91 182
1998 84 96 180
1999 100 91 191
2000 87 99 186
2001 94 98 192
2002 88 106 194
2003 106 127 233
2004 177 183 360than expected, but in comparison was lower among pa-
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23.1% P  .01; Table IV). Of the 280 patients readmitted,
31.7% were patients with claudication. Reinterventions
were required in 28% of readmitted patients with claudica-
tion and in 41.4% of all others. None of the 37 lower limb
amputations performed during readmissions were per-
formed on patients with claudication.
Internal validation. Internal validation of the admin-
istrative coding strategy for patient selection was performed
with a concurrent clinical database at one of our institu-
tions. Internal validation was performed by examining
records of procedures from a single institution for 2004 and
then comparing them with the results from the CHARS
sample for the same institution during that year. Records
included for validation contained CPT codes (American
Medical Association, Chicago, Ill) for transluminal angio-
plasty, percutaneous placement of a stent, and radiologic
supervision and interpretation. Records were subjected to
the same exclusion criteria (eg, carotid, renal or aortic
disease). The capture rate of the data set was 70% for this
single institution, with the breakdown of clinical indica-
tions similar to the administrative codes found in the dis-
charge database.
DISCUSSION
The use of PTA for claudication dramatically increased
Table II. Population characteristics
Characteristic Percentages (N  1718)*
Age (years) 69.7  11.7
Sex
Male 52.4
Charlson index category
0 43.3
1 35.3
2 14.4
3 7.0
Admission source
Outpatient 89.2
Trans/care facility 1.9
Emergency department 9.0
Admission type
Elective 78.6
Urgent 13.3
Emergency 8.1
Insurance
Medicare 66.2
Private 26.3
Medicaid 5.6
Length of stay (days) 3.8  4.5
Surgery types
Stent 61.3
Diagnoses
Claudication 51.9
Rest pain 12.1
Ulceration/gangrene 23.2
Other/NOS 12.9
NOS, Not otherwise specified.
*Continuous data are expressed as mean  standard deviation.in the 8-year study period. Claudication was more often thediagnosis for PTA in patients who were younger, healthier,
and privately insured. PTA for claudication was associated
with a higher-than-expected rate of 30-day mortality, read-
mission, and reintervention, but no amputations occurred
30 days of the procedure. Future studies will focus on the
factors motivating its growing use, its other associated
outcomes, and its global impact on patients and the health
care system.
Population-based research is an important adjunct to
outcomes assessment because the results of commonly
performed procedures in the community at large often
differ from the reported findings in small case series by
practitioners with a particular and unique experience with
these techniques. Community-based evaluations reflect
more of a real-world appraisal that encompasses the varied
patient selection, different skill levels of practitioners, pro-
cedure performance characteristics, and associated out-
come in a less controlled environment. Linked administra-
tive databases such as CHARS allow for a near complete
Table III. Population characteristics by diagnosis
Claudication
(%)* n  891
All other
diagnoses (%)*
n  827 P
Age (years) 67.9  10.3 71.7  11.7 .01
Sex .01
Male 58.2 46.2
Female 41.8 53.8
Charlson index category .01
0 49.2 36.9
1 37.2 33.2
2 11 18.1
3 2.7 11.7
Admission type .01
Elective 90.2 66.1
Urgent 7.1 20
Emergency 2.7 13.9
Private insurance 32.1 20 .01
Length of stay (days) 2.4  2.3 5.3  5.8 .01
Associated procedures (%)
Stent 67.0 55.1 .01
Discharge Status .01
Home 94.2 66.3
Home with aid 1.9 10.0
Care facility 3.0 20.3
Hospice 0.1 0.1
In-hospital death 0.8 3.3
*Continuous data are expressed as mean  standard deviation.
Table IV. Unadjusted outcomes, by diagnosis
Claudication (%)
n  891
All other
diagnoses (%)
n  827 P
30-day mortality 1.2 4.7 .01
Readmission (30 day) 10.0 23.1 .01
Reintervention for
readmits 28.1 47.6 .01longitudinal follow-up of cohorts, and this may be impor-
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tion.
A large number of case series have reported the use of
infrainguinal and lower extremity angioplasty.10-16 Multi-
ple series have suggested that PTA and stenting of the lower
extremities can be performed safely and with excellent
procedural and short-term success rates. The patients in
many of these series have not been consistently followed up
over time, and the completeness of calculated rates of
reintervention and complication (range, 2% to 7%) cannot
be assessed. These series suffer from selection and publica-
tion bias and may not represent practice conditions outside
of these centers.
Little information has been published describing the
readmission and reintervention rates after endovascular
procedures on the lower extremities. Most studies describe
a very low rate of periprocedural complications without
longitudinal follow-up. In this study, we evaluated 30-day
readmission data to be more certain that secondary proce-
dures were being performed on the same extremity. It is
possible that some of the patients were admitted for sec-
ondary procedures on the contralateral leg during that time,
butwe hoped to limit that by truncating the follow-up period.
Nowygrod et al5 also looked at the trends in complica-
tions and mortality in vascular surgery. That study used the
hospital admission databases of four states to examine
deaths after lower extremity revascularization. They re-
ported onmortality rates of 1.5% to 2% and noted codes for
postoperative complications, including cardiac events,
stroke, respiratory events, bleeding, infection, and shock
being approximately 10%. Unfortunately, that study did
not separate interventions by diagnosis type and did not
have longitudinal outcomes or readmission data.
Longitudinal follow-up has been also been reported in
case series. For example, Schillinger et al17 reported 3
month restenosis in 23% of patients having angioplasty and
14% for those undergoing stenting. The 30-day reinterven-
tion was 2%. They reported for early complications that
one patient in the stent group had an early thrombotic
reocclusion the day after the intervention.17 Other authors
have also suggested very low 30-day periprocedural com-
plications, including 3 in 98 patients,15 0 at 30 days for
subintimal angioplasty,11 3 at 30 days (1.1%) for iliac
stenting,18 and 1 of 62 with reangioplasty in a 2-year
follow-up.19
Another trial evaluating angioplasty in severe leg isch-
emia was the Bypass Versus Angioplasty in Severe Ischemia
of the Leg (BASIL) trial.16 This series reported no 30-day
deaths, a morbidity of approximately 20% (of which read-
mission is not listed), and a 7% reintervention rate in a
cohort of patients with lower extremity disease who were
considered sicker than the general population of patients. It
is therefore interesting that our cohort drawn from nearly
the entire population of Washington State residents under-
going these procedures found a 30-day readmission rate of
10%. Although the case series and reports suggest that the
rate of periprocedural reintervention and complications is
very low, it appears that population level results are not asgood.Most studies (including our own) have not evaluated
the important long-term outcomes of patency and limb
function over time.
To varying extents, there appears to be a movement in
the fields of vascular surgery, interventional radiology, and
cardiology to apply endovascular interventions to condi-
tions that are quality-of-life or functionally limiting, rather
than limb-threatening.20 Many advocate early endovascular
intervention for claudication as a first-line therapy.6,20-22
Early intervention for claudication is a significant modifica-
tion from the traditional treatment algorithm of behavioral
therapy (eg, cigarette cessation and exercise programs) and
medical therapy.
This trend of early PTA is not supported by evi-
dence,8,23,24 and although the short-term patency of lower
extremity PTA and stenting is acceptable,25 f e w long-term
data are available. There have been few appropriately designed
randomized trials evaluating angioplasty and conventional
surgery for the treatment of severe limb-threatening isch-
emia due to infrainguinal disease showing both bypass-
surgery-first and balloon-angioplasty-first strategies were
associated with similar outcomes in terms of amputation-
free survival.16 Whether these findings are reproduced in
patients with claudication is unclear. What is certain is that
this evolution in care has not been well studied and neither
have its important implications for the field of vascular
surgery, vascular medicine, and the healthcare system. It
remains to be determined whether the current treatment
paradigm for claudication19,26-28 represents an appropriate
abandonment of the age-old dictum of nonintervention.
This study also raises important questions about the
forces driving the increased use of PTA for claudication.We
found that patients with claudication undergoing PTA
were more likely to have commercial insurance, to be
younger, and to be healthier than those undergoing PTA
for other reasons. This may be an important observation
suggesting that socioeconomic or reimbursement factors,
or both, may be driving an increase in this technology for
patients with claudication. Claudicant patients were more
likely to be insured and thus may be more likely to have
more procedures performed for reimbursement. Stenting
procedures have a higher reimbursement, and this may
account for the discrepancy seen in a high percentage of
patients with claudication receiving stents.
This question of socioeconomic factors driving the
increased use of PTA requires further evaluation to assess
the factors involved. These potential factors may be patient
demands, physician training and specialty, and commercial
forces. Alternatively, commercial insurance status may sim-
ply be a marker associated with patients who use more
health care resources in an appropriate fashion and not a
predictor of inappropriate use.
This study has several limitations. The CHARS data-
base did not include patients in military hospitals, Veterans
Administration medical centers, or Washington residents
who underwent PTA in the state and immediately moved
to a different state. It is also likely that the frequency of PTA
has been underestimated, because this data set only cap-
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patient procedures. This may serve as a selection bias, given
that healthier individuals are more likely to have outpatient
procedures. The potential for inclusion bias because of
limited coding schemes for this clinical entity also cannot be
excluded.
The CHARS database does not contain information on
the discipline of the treating physician. What can be as-
sessed is that 90% of the patients with claudication under-
going procedures were elective, implying that patients were
admitted for these procedures. As well, the CHARS data-
base considers an inpatient admission as the formal accep-
tance by a health facility of a patient who is to be provided
with room, board, and continuous nursing service in an
area of the facility where patients generally stay at least
overnight.
The Charlson Index is intended to adjust for comorbid
illnesses, it does not incorporate the degree of illness, nor
has it been specifically applied to the population of patients
undergoing PTA. As well, confounding by indication is
relevant when comparing outcomes for patients undergo-
ing PTA for claudication compared with other conditions.
Patients who had a PTA for reasons other than claudication
were older, had more comorbidities, were more likely to be
men, and were more likely to have Medicare/Medicaid as
their payer. These variables all have a role in adverse out-
come independent of the intervention received. Finally, we
used patient status as aMedicaid beneficiary or uninsured as
a proxy of socioeconomic status29,30 owing to lack of more
direct assessments.
CONCLUSION
This evaluation of statewide outcomes after lower ex-
tremity PTA demonstrated that at least half of the proce-
dures were performed on patients who had claudication as
their only associated diagnosis. We found rates of readmis-
sion and reintervention after PTA among patients with
claudication that were higher than previously reported. The
availability of less invasive endovascular procedures has
grown in the absence of data on effectiveness. An evidence
base needs to be developed to help guide clinicians to the
most effective management for PAD, and the forces driving
the increased use of PTA for claudication need to be more
completely assessed.
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